Therapeutic Areas

Latest News

Image credit: peterschreiber.media | stock.adobe.com
Data From Phase III Extension Trial Show Long-Term Safety, Efficacy of Qulipta in Migraine Prevention

April 12th 2024

Multicenter, open-label, 156-week extension trial finds that Qulipta (atogepant) reduced migraine days and acute medication use in patients with chronic or episodic migraine.

Image credit: cendeced | stock.adobe.com
Meta-Analysis of Randomized Clinical Trials Show Psilocybin for Depression, Anxiety Has Tolerable Adverse Effects

April 11th 2024

Image credit: jarun011 | stock.adobe.com
Phase III Trial Data Show Efficacy of Abrysvo in Adults Aged 18 to 59 Years with Elevated Risk of Severe RSV

April 9th 2024

Image credit: peterschreiber.media | stock.adobe.com
Phase III Trial Data Show Jardiance Falls Short of Statistical Significance in Reducing Risk of Heart Failure Hospitalization, Death Following Heart Attack

April 8th 2024

Image credit: Kristina Blokhin | stock.adobe.com
FDA Accepts sBLA for Bimzelx to Treat Hidradenitis Suppurativa Based on Phase III Trial Data

April 4th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.